[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-349959-105":59,"doc-detail-349959-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","the-key-m6a-methylation-regulator-igf2bp1-possesses-potential-prognostic-value-in-papillary-thyroid-carcinoma","The key m6A methylation regulator IGF2BP1 possesses potential prognostic value in papillary thyroid carcinoma","","Papillary thyroid carcinoma (PTC) has recurrence risk and limited treatment efficacy, creating a need for new prognostic biomarkers and therapeutic targets. Using The Cancer Genome Atlas, 17 m6A regulators were assessed, showing marked downregulation of IGF2BP1 in PTC while higher IGF2BP1 expression predicts improved 5-year survival as an independent prognostic factor. Elevated IGF2BP1 also suggests greater sensitivity to doxorubicin and sunitinib, links low IGF2BP1 to central lymph-node metastasis and BRAFV600E mutation, and indicates IGF2BP1 overexpression suppresses tumor cell proliferation, invasion, and migration.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/the-key-m6a-methylation-regulator-igf2bp1-possesses-potential-prognostic-value-in-papillary-thyroid-carcinoma/349959/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/the-key-m6a-methylation-regulator-igf2bp1-possesses-potential-prognostic-value-in-papillary-thyroid-carcinoma/349959.png","ImageObject",300,407,{"name":92,"@type":93},"Valentina","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-03","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the clinical problem addressed in this study?","Question",{"text":112,"@type":113},"Papillary thyroid carcinoma has a risk of recurrence and current treatments have limited efficacy, so improved prognostic markers and therapeutic targets are needed.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was IGF2BP1 evaluated as a prognostic factor?",{"text":117,"@type":113},"The study analyzed 17 m6A regulators in PTC using The Cancer Genome Atlas and found that higher IGF2BP1 expression predicts better 5-year survival as an independent prognostic marker.",{"name":119,"@type":110,"acceptedAnswer":120},"What relationship does IGF2BP1 have with treatment sensitivity and disease features?",{"text":121,"@type":113},"Higher IGF2BP1 expression indicates greater sensitivity to doxorubicin and sunitinib, while low IGF2BP1 is associated with central lymph-node metastasis and the BRAFV600E mutation.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},349959,1790141647,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":41,"preview_page_count":19,"preview_urls":145},13056703020460,"https://ap-avatar.wpscdn.com/avatar/be000253dac470eee5d?_k=1778207105932848923","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nThe key m6A methylation regulator IGF2BP1 possesses potential prognostic value in papillary thyroid carcinoma  \nJinqiu Wang1, Chen Dai2, Mingze Wei1, Weida Fu1, Jin Luo1 & Yongping Dai1􀀍  \nPapillary thyroid carcinoma (PTC) poses a risk of recurrence, and the efficacy of existing treatments is limited. Consequently, there is an urgent need to identify new prognostic markers and potential therapeutic targets. N6-methyladenosine (m6A) mRNA methylation is involved in tumorigenesis and progression, yet the role of m6A RNA methylation regulators in PTC remains unclear. The Cancer Genome Atlas database was utilized to analyze 17 m6A regulators in PTC. Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) was markedly down-regulated in PTC, yet higher IGF2BP1 expression predicts better 5-year survival, acting as an independent prognostic marker with high accuracy. Elevated IGF2BP1 also indicated greater sensitivity to doxorubicin and sunitinib. Clinically, low IGF2BP1 correlated with central lymph-node metastasis and BRAFV600E mutation. Additionally, IGF2BP1 overexpression suppresses thyroid carcinoma cell proliferation, invasion, and migration. In conclusion, High expression of IGF2BP1 was associated with a favorable prognosis in PTC, and it served as an independent prognostic factor and a potential therapeutic target for PTC.  \nKeywords Papillary thyroid carcinoma, IGF2BP1, N6-methyladenosine, Predictive factor  \nThyroid cancer (TC) ranks among the most prevalent cancers globally1, with its incidence rate rising rapidly and accounting for 1–2% of all cancer cases2. Based on pathological classification, TC can be categorized into papillary thyroid cancer (PTC), follicular thyroid cancer, medullary thyroid cancer, and anaplastic thyroid cancer. Among these types, PTC is the most frequently occurring, representing over 80% of cases3. For patients diagnosed with PTC, surgical procedures, thyroid-stimulating hormone suppression therapy, and 131I treatment significantly influence their prognosis4. Nevertheless, despite these interventions, more than 10% of patients still experience recurrence5. Moreover, current treatment approaches have limited efficacy in managing local tumor progression and distant metastasis in PTC patients. Consequently, identifying effective diagnostic markers, prognostic indicators, and therapeutic targets for PTC is of utmost importance.  \nN6-methyladenosine (m6A) methylation is the most prevalent post-transcriptional modification of mRNA, participating in various biological processes, such as tumor proliferation, invasion, and epithelialmesenchymal transition (EMT)6. It has been reported that three types of proteins collaborate to maintain the balance of the m6A network: methyltransferase complexes, m6A-binding proteins, and demethylases. Among them, the methyltransferase complex comprises methyltransferase-like 3 (METTL3), methyltransferase-like 14 (METTL14), methyltransferase-like 16 (METTL16), RNA binding motif protein 15 (RBM15), RNA binding motif protein 15B (RBM15B), wilms tumor 1 associating protein (WTAP), and KIAA1429 protein (KIAA1429) . Them6A-binding proteins include YTH domain-containing protein 1 (YTHDC1), YTH domain-containing protein  \n2 (YTHDC2), YTH N6-methyladenosine RNA binding protein 1 (YTHDF1), YTH N6-methyladenosine RNA binding protein 2 (YTHDF2), YTH N6-methyladenosine RNA binding protein 3 (YTHDF3), insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1), insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2), insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3), heterogeneous nuclear ribonucleoprotein A2/ B1 (HNRNPA2B1), and heterogeneous nuclear ribonucleoprotein C (HNRNPC) . The demethylases include fat mass and obesity-associated protein (FTO) and AlkB homolog 5, alpha-ketoglutarate-dependent dioxygenase (ALKBH5). This intricate regulatory network is deeply involved in the ma","cbCaidIbGoEWY3vs","https://ap.wps.com/l/cbCaidIbGoEWY3vs","pdf",2698833,12,"English","# Introduction\n## Background on PTC and the need for prognostic markers\n## m6A RNA methylation regulators and their roles in tumors\n# Materials and methods\n## Overview of TCGA-based analysis and subgrouping\n## Risk model construction and validation experiments\n## Evaluation of IGF2BP1 expression and cellular assays","[{\"question\":\"What is the clinical problem addressed in this study?\",\"answer\":\"Papillary thyroid carcinoma has a risk of recurrence and current treatments have limited efficacy, so improved prognostic markers and therapeutic targets are needed.\"},{\"question\":\"How was IGF2BP1 evaluated as a prognostic factor?\",\"answer\":\"The study analyzed 17 m6A regulators in PTC using The Cancer Genome Atlas and found that higher IGF2BP1 expression predicts better 5-year survival as an independent prognostic marker.\"},{\"question\":\"What relationship does IGF2BP1 have with treatment sensitivity and disease features?\",\"answer\":\"Higher IGF2BP1 expression indicates greater sensitivity to doxorubicin and sunitinib, while low IGF2BP1 is associated with central lymph-node metastasis and the BRAFV600E mutation.\"}]","The key m6A methylation regulator IGF2BP1 possesses potential prognostic value in papillary thyroid carcinoma | PDF",1790086471,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/dc3e4d7f697defa65f21214628366ab2.webp",983,1291,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/878e70276756562f123430c6f89de1c5.webp",982,1290,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/be77c4d0d9ac2524b5d330cc06fd0732.webp",981,1289,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4bbda0b404aa174640c81b749a512c38.webp",980,1287]